CDX-622 is a novel, bispecific antibody combining mast cell depletion and TSLP inhibition, two independent pathways contributing to multiple I&I diseasesCDX-622 targets the soluble form of stem cell factor (SCF), depleting mast cells without measurab

Achieved 100% ORR and 83.3% CR rate at dose level 2 following a single infusion in patients with relapsed/refractory B-NHL in an ongoing Phase 1 studySingle infusion of LB2501 generated dose-dependent in vivo CAR-T expansion without lymphodepletionNo

Multi-organ system and quality-of-life benefits sustained through three and a half years 86% response rate for the multi-component endpoint 89% of patients completed the three-and-a-half-year trial COPENHAGEN, Denmark, June 13, 2026 (GLOBE NEWSWIRE)

Richard Roths Media confirms a $52 million investment from GGC Capital Investment Group to expand its AI-driven marketing system for high-trust industries, according to Richard Rothschild, Founder and CEO of Richard Roth's Media.Beverly Hills, Califo

Mitapivat demonstrated statistically significant improvement in hemoglobin response compared with placebo, with rapid onset and durable effectsNew analyses showed patients in mitapivat arm had clinically meaningful reduction in transfusion burden com

-- Patients with PWS treated with setmelanotide therapy (N=17) achieved clinically meaningful BMI or BMI z-score reductions, reductions in fat mass with preservation of lean mass, and improvements in hyperphagia and anxiety measures -- -- Positive re

Data from HAELO Phase 3 clinical trial presented today in a late-breaking oral session at European Academy of Allergy & Clinical Immunology Annual Congress 2026HAELO manuscript simultaneously published in the New England Journal of Medicine CAMBRIDGE

Mexico City, Mexico--(Newsfile Corp. - June 13, 2026) - As UFC lightweight champion Ilia Topuria prepares for one of the biggest fights of his career, international brand 1win highlights the recent acceptance of the undefeated MMA superstar to the 1w

DALLAS, June 12, 2026 (GLOBE NEWSWIRE) -- Arcadia Biosciences, Inc.® (Nasdaq: RKDA), a producer and marketer of innovative wellness products, announced today the closing of its previously announced private placement priced at-the-market under Nasdaq

SAN DIEGO, June 12, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have signific